Physician profile
Keith W Cushing
NPI 1043437395
$5,711.87
in general payments reported to CMS, 2019-2025
38 companies · $87.90 in 2025
The $87.90 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $250 · 2020: $215 · 2021: $1,850 · 2022: $2,769 · 2023: $408 · 2024: $132 · 2025: $87.90.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $543 · Education: $85.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.51 |
| Education | $85.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $757.50 | 2020-2023 | |
| Abbvie INC. | $752.81 | 2021-2025 | Duopa |
| Supernus Pharmaceuticals, INC. | $559.78 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $497.42 | 2021-2023 | Austedo |
| Amgen INC. | $456.78 | 2021-2023 | Aimovig |
| Harmony Biosciences LLC | $322.71 | 2021-2023 | Wakix |
| Sk Life Science, INC. | $236.39 | 2020-2022 | |
| Jazz Pharmaceuticals INC. | $230.79 | 2021-2023 | |
| Neurocrine Biosciences, INC. | $179.53 | 2022 | |
| Vanda Pharmaceuticals INC. | $178.68 | 2022-2023 | Fanapt, Hetlioz |
| Catalyst Pharmaceuticals, INC. | $168.01 | 2022-2025 | |
| Biogen, INC. | $153.99 | 2022-2023 | Vumerity |
| Janssen Pharmaceuticals, INC | $148.98 | 2021-2022 | |
| Ucb, INC. | $112.74 | 2021 | |
| Genzyme Corporation | $111.42 | 2021-2022 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aprecia Pharmaceuticals, LLC | $104.86 | 2021-2023 | Spritam |
| Novartis Pharmaceuticals Corporation | $96.61 | 2022-2024 | |
| Mdd US Operations, LLC | $87.64 | 2022-2024 | Apokyn, Apokyn |
| Lilly USA, LLC | $74.55 | 2019-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $51.38 | 2022 | |
| Acadia Pharmaceuticals INC | $46.22 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.63 | 2022-2023 | Gammagard |
| Neurelis, INC. | $43.44 | 2022 | |
| Livanova USA, INC. | $42.17 | 2022 | |
| Collegium Pharmaceutical, INC. | $30.21 | 2022 | |
| Horizon Therapeutics Plc | $26.44 | 2022 | |
| Arbor Pharmaceuticals, INC. | $26.32 | 2021 | |
| Amneal Pharmaceuticals LLC | $25.62 | 2022 | |
| Corium, LLC | $21.18 | 2022 | |
| Upsher-Smith Laboratories LLC | $19.17 | 2021 | |
| Abbott Laboratories | $16.54 | 2019 | |
| Celgene Corporation | $15.25 | 2022 | |
| Emd Serono, INC. | $13.17 | 2019 | |
| Impel Pharmaceuticals INC. | $12.16 | 2022 | |
| Almatica Pharma LLC | $12.08 | 2021 | |
| Avion Pharmaceuticals | $11.94 | 2021 | |
| Genentech USA, INC. | $11.67 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Cushing listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.